Dr. Csiki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd.
Rad Onc/Trc 2 West
Philadelphia, PA 19104Phone+1 215-662-2428
Education & Training
- Vanderbilt University Medical CenterResidency, Radiation Oncology, 2008 - 2012
- Vanderbilt University Medical CenterInternship, Internal Medicine, 2007 - 2008
- Vanderbilt University School of MedicineClass of 2007
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN Start of enrollment: 2019 Nov 11
- SNS-301 Monotherapy in High Risk MDS and CMML Start of enrollment: 2020 Apr 01
Publications & Presentations
PubMed
- 14 citationsPersonalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan
Nature Medicine. 2024-04-01 - 90 citationsImmunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow, Kimberly A. Kraynyak, Albert Sylvester
Clinical Cancer Research. 2019-01-01 - 147 citationsQuantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in...Laine J. Murphey, Myles K. Williams, Stephanie C. Sanchez, Loretta M. Byrne, Ildiko Csiki
Analytical Biochemistry. 2004-11-15
Press Mentions
- Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of Its Scientific Advisory BoardJuly 21st, 2021
- Development of a Multi-Antigenic SARS-CoV-2 Vaccine Candidate Using a Synthetic Poxvirus PlatformNovember 30th, 2020
- Chutes & Ladders—Novavax Appoints AstraZeneca Vet Dubovsky to CMO RoleJune 19th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: